Background: The incidence of squamous cell carcinoma (SCC) and adenocarcinoma of the bladder have been higher than that of urothelial carcinoma (UC) in several African countries for nearly five decades. However, this trend has changed over time, with ...
Objective: Despite the remarkable improvement in gastric adenocarcinoma treatment modalities, the prognosis of gastric adenocarcinoma remains poor. The purpose of this study was to determine the prevalence of HER2 immunohistochemical expression and its association with clinicopathological features of patients with gastric adenocarcinoma. Material and Methods: This was a cross-sectional study which was conducted at the department of pathology. A total of 86 formalin fixed paraffin embedded tissue blocks of the patients who were confirmed histologically with gastric adenocarcinoma from January 2009 to December 2019 were included in the analysis. Laboratory requisition form and patients’ files were used to extract the clinical and pathological data of the cases. Immunohistochemistry to assess HER2 overexpression was done using monoclonal (SP3 clone) rabbit anti-HER2/neu (Thermo Fisher Scientific-USA). Chi-square statistical test was used to determine the association of the clinicopathological characteristics with HER2 expression. P< 0.05 was considered statistically significant. Results: Mean age of the patients included in the study was 58.5 ± 14.3 years, and over half 54.7% (n= 47) of the patients were males. Poorly cohesive non-signet ring types contributed most (47.7%) (n= 41) of the cases, and diffuse/mixed histological subtypes were more prevalent (57%) (n= 49) subtypes. Poorly differentiated cases accounted for the majority (66.3%) (n= 57) of the cases. The prevalence of HER2 immunohistochemical expression was 8.1% (n= 7). None of the clinicopathological characteristics were associated with HER2 expression. Conclusion: This study has shown almost every one in 10 patients with gastric adenocarcinoma may express HER2 when using immunohistochemistry test. However, the HER2 in this study was not associated with age, sex, tumor location, the nature of biopsy, histological subtypes, and tumor grade.
Tumour-infiltrating lymphocytes (TILs) are established biomarkers of breast cancer immunogenicity and prognosis. Reproductive events induce durable immunological remodelling of the breast, but whether TIL levels at diagnosis reflect the immunological imprint of these events remains unclear. We included women diagnosed with invasive breast cancer between 1978 and 2012 in the Energy Balance and Breast Cancer Aspects throughout Life study, a substudy of the population-based Tromsø Study (Norway). Prediagnostic host factors were obtained. TILs were scored on an ordinal scale (1-4). Associations between host factors and the TIL score were analysed using ordinal logistic regression with interaction terms for hormone receptor (HR) status. Breast cancer-specific mortality was evaluated using Kaplan-Meier methods and Cox regression. A total of 425 women were included [median age at diagnosis 56.0 years, 360 (87.6%) parous], of whom 84 (19.8%) had HR-negative tumours. Among HR-negative cases, parity [odds ratio (OR) 10.14, 95% confidence interval (CI) 1.97-52.22], longer breastfeeding duration [OR 1.87 per standard deviation (SD), 95% CI 1.10-3.17], and higher age at first birth (OR 1.79 per SD, 95% CI 1.06-3.01) were associated with higher TIL scores, whereas higher mean arterial pressure (OR 0.59 per SD, 95% CI 0.41-0.86) was inversely associated. Significant interactions with HR status were observed for parity and breastfeeding duration. No associations were observed in HR-positive tumours. High-TIL levels (scores 3-4 versus 1-2) were associated with lower breast cancer-specific mortality in HR-negative tumours (adjusted hazard ratio 0.32, 95% CI 0.14-0.72) but not in HR-positive disease (hazard ratio 0.98, 95% CI 0.58-1.68; Pinteraction = 0.023). These findings suggest that reproductive history and timing may shape the tumour immune microenvironment over the life course. If confirmed in larger studies, TILs may represent an intermediate phenotype linking upstream host characteristics to downstream clinical outcomes in breast cancer.
1 January 2024 in Obstetrics and Gynecology International
Background:BRCA1 gene dysfunction seen in epithelial ovarian carcinomas often results from germline mutations, somatic mutations, and promoter methylation. Identification of tumors with loss of BRCA1 protein expression has shown to have therapeutic and prognostic implications. The aim of this study was to determine the expression of BRCA1 protein in epithelial ovarian cancer (EOC) and the associated clinicopathological characteristics.Methods and Results: This was a cross‐sectional laboratory‐based study that used paraffin‐embedded tissue blocks of patients histologically diagnosed with EOC from January 2010 to August 2018. Tissue sections were stained with hematoxylin and eosin (H&E) for histological confirmation and with immunohistochemistry (IHC) using a mouse‐derived monoclonal antibody MS110 for BRCA1 protein expression. The association between BRCA1 protein expression and independent variables was determined using Pearson’s Chi‐square test. A total of 104 tissue blocks from patients with EOC were included in the study with a mean age of 48.7 ± 12.8 years. Serous tumors were the most common which comprised 74.0% (77/104) of all the tumors and majority of them 75.3% (58/77) were high grade. Loss of expression of BRCA1 protein expression was found in 33.7% (33/98) of all the cases. There was no statistically significant association between BRCA1 expression and age of patients, tumor grade, and histological subtype.Conclusion: There is a high expression of altered BRCA1 expression in tissues of EOC. Although it has not shown association with age of patients, histology types, and tumor grade, further studies need to assess its influence of the survival of cancer patients with EOC.